MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$226.365M
Free Cash flow
$218.884M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Receivable from collaboration pa...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Purchase of marketable securitie...
Accounts payable
Contract asset
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
162.849
3.783
-44.384
-39.339
Stock-based compensation
14.037
14.519
10.701
10.559
Non-cash lease expense
0.444
0.439
0.345
0.106
Depreciation
0.397
0.407
0.376
0.361
Accretion of discount on marketable securities
1.046
1.025
1.336
1.684
Net realized loss on sale of marketable securities
-
-
-
0.001
Other
-0.002
-0.002
-0.008
-
Receivable from collaboration partner
-40.247
53.542
-0.462
0.583
Contract asset
3.366
-
-
-
Prepaid expenses and other assets
-4.217
1.918
0.365
-0.05
Accounts payable
-4.9
3.003
-0.307
2.418
Accrued expenses and other payables
4.19
-10.792
5.409
7.545
Income taxes payable
-
-
0
0
Deferred revenue
3.377
-3.268
-7.438
-3.075
Operating lease liability
-0.56
-0.547
1.38
-0.477
Other non-current assets
0.832
-
-
-
Net cash provided by operating activities
219.052
-48.943
-36.975
-1.937
Purchase of marketable securities
134.676
68.968
104.274
161.117
Proceeds from maturities of marketable securities
132.414
156.691
153.233
102.65
Proceeds from sale of marketable securities
0
3.384
0
0
Purchases of property and equipment
0.168
0.215
0.144
0.088
Net cash provided by (used in) investing activities
-2.43
90.892
48.815
-58.555
Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan
9.743
23.374
2.837
5.659
Tax withholding payments related to net settlement of restricted stock units
-
-
0
0
Net cash provided by financing activities
9.743
23.374
2.837
5.659
Net increase in cash, cash equivalents and restricted cash
226.365
65.323
14.677
-54.833
Cash, cash equivalents and restricted cash, beginning of period
194
128.677
114
97.474
Cash, cash equivalents and restricted cash, end of period
420.365
194
128.677
114
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income (loss)
$162.849M
(450.77%↑ Y/Y)
Receivable from
collaboration partner
-$40.247M
(75.61%↑ Y/Y)
Stock-based compensation
$14.037M
(-43.20%↓ Y/Y)
Prepaid expenses and
other assets
-$4.217M
(-306.21%↓ Y/Y)
Proceeds from issuance of
common stock upon...
$9.743M
(-34.38%↓ Y/Y)
Accrued expenses and
other payables
$4.19M
(150.01%↑ Y/Y)
Deferred revenue
$3.377M
(132.15%↑ Y/Y)
Non-cash lease expense
$0.444M
(-60.95%↓ Y/Y)
Depreciation
$0.397M
(-26.89%↓ Y/Y)
Net cash provided by
operating activities
$219.052M
(126.80%↑ Y/Y)
Net cash provided by
financing activities
$9.743M
(-32.19%↓ Y/Y)
Canceled cashflow
$10.706M
Net increase in
cash, cash...
$226.365M
(217.22%↑ Y/Y)
Canceled cashflow
$2.43M
Accounts payable
-$4.9M
(-403.97%↓ Y/Y)
Contract asset
$3.366M
(-84.90%↓ Y/Y)
Accretion of discount on
marketable securities
$1.046M
(-75.11%↓ Y/Y)
Other non-current
assets
$0.832M
Operating lease liability
-$0.56M
(-638.46%↓ Y/Y)
Other
-$0.002M
Proceeds from maturities
of marketable...
$132.414M
(-43.88%↓ Y/Y)
Net cash provided by
(used in) investing...
-$2.43M
(93.86%↑ Y/Y)
Canceled cashflow
$132.414M
Purchase of marketable
securities
$134.676M
(-52.11%↓ Y/Y)
Purchases of property and
equipment
$0.168M
(-87.63%↓ Y/Y)
Buy us a coffee
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)